scholarly journals Randomized phase II/III confirmatory treatment selection design with a change of survival end points: Statistical design of Radiation Therapy Oncology Group 1216

Head & Neck ◽  
2018 ◽  
Author(s):  
Qiang (Ed) Zhang ◽  
Qian Wu ◽  
Paul M. Harari ◽  
David I. Rosenthal
Keyword(s):  
Radiation Therapy ◽  
Phase Ii ◽  
Radiation Therapy Oncology Group ◽  
Statistical Design ◽  
Treatment Selection ◽  
Oncology Group ◽  
End Points ◽  
Randomized Phase Ii

Preliminary Results of Radiation Therapy Oncology Group 97-03: A Randomized Phase II Trial of Concurrent Radiation and Chemotherapy for Advanced Squamous Cell Carcinomas of the Head and Neck

2004 ◽  
Vol 22 (14) ◽  
pp. 2856-2864 ◽  
Author(s):  
A.S. Garden ◽  
J. Harris ◽  
E.E. Vokes ◽  
A.A. Forastiere ◽  
J.A. Ridge ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Head And Neck ◽  
Phase Ii ◽  
Phase Ii Trial ◽  
Radiation Therapy Oncology Group ◽  
Squamous Carcinoma ◽  
Institutional Setting ◽  
Oncology Group ◽  
Randomized Phase Ii ◽  
To Receive

Purpose To define further the role of concurrent chemoradiotherapy for patients with advanced squamous carcinoma of the head and neck. Patients and Methods The Radiation Therapy Oncology Group developed this three-arm randomized phase II trial. Patients with stage III or IV squamous carcinoma of the oral cavity, oropharynx, or hypopharynx were eligible. Each of three arms proposed a radiation schedule of 70 Gy in 35 fractions. Patients on arm 1 were to receive cisplatin 10 mg/m2 daily and fluorouracil (FU) 400 mg/m2 continuous infusion (CI) daily for the final 10 days of treatment. Treatment on arm 2 consisted of hydroxyurea 1 g every 12 hours and FU 800 mg/m2/d CI delivered with each fraction of radiation. Arm 3 patients were to receive weekly paclitaxel 30 mg/m2 and cisplatin 20 mg/m2. Patients randomly assigned to arms 1 and 3 were to receive their treatments every week; patients on arm 2 were to receive their therapy every other week. Results Between 1997 and 1999, 241 patients were entered onto study; 231 were analyzable. Ninety-two percent, 79%, and 83% of patients on arms 1, 2, and 3, respectively, were able to complete their radiation as planned or with an acceptable variation. Fewer than 10% of patients had unacceptable deviations or incomplete chemotherapy in the three arms. Estimated 2-year disease-free and overall survival rates were 38.2% and 57.4% for arm 1, 48.6% and 69.4% for arm 2, and 51.3% and 66.6% for arm 3. Conclusion We have demonstrated that three different approaches of concurrent multiagent chemotherapy and radiation were feasible and could be delivered to patients in a multi-institutional setting with high compliance rates.

Sign in / Sign up

Export Citation Format

Share Document